AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The underperformance is significant for investors to consider because AstraZeneca’s operating results have remained relatively strong, and that makes its valuation more interesting. Instead of asking whether the stock is simply cheap after falling, investors need to determine whether the company’s earnings and pipeline can support a recovery.
AstraZeneca has lagged the broader market, but certain other healthcare stocks haven’t. Check our list of the best healthcare stocks to buy according to hedge funds to gain deeper insight into the sector and make an informed investment decision.
Is 14.6 Times Forward Earnings Cheap?
Yahoo Finance puts AstraZeneca’s forward P/E at approximately 14.6x based on its latest available valuation data. That is considerably below the company’s trailing multiple of 25.21 and gives investors a relatively modest price for a pharmaceutical business that is still targeting double-digit earnings growth.
AstraZeneca’s 2026 results provide some context here. Total revenue rose 6% in H1 2026, with the company reporting double-digit growth in Oncology and Rare Disease. For 2026, management reaffirmed guidance for total revenue growth in the mid-to-high single digits and core EPS growth in the low double digits, both at constant exchange rates. That combination makes 14.6x earnings look less demanding than the headline trailing P/E suggests. Gain deeper insight into AZN’s bull and bear cases by going through our insightful discussion on AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue?
Oncology Is Carrying Much of the Growth
AstraZeneca’s first-half 2026 results show where that earnings growth is coming from. Total revenue increased 6% at constant exchange rates to $30.67 billion, while core EPS increased 11%. Oncology, the company’s largest therapy area, generated $14.1 billion and grew 15%, while Rare Disease revenue increased 11% to $4.9 billion.
The pipeline provides another reason the valuation may be sustainable. AstraZeneca reported 183 projects in its pipeline at the end of the first half, including 21 new molecular entities in late-stage development. That pipeline helps build the bull case for AstraZeneca since the company needs new medicines to offset the eventual pressure that comes with mature products losing exclusivity. We discussed AZN’s oncology growth in great detail in our recently published article on AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?. Read the full discussion here.
Growth Is Not Evenly Distributed
The headline numbers hide some weaker areas. BioPharmaceuticals revenue declined 5% in the first half, with Cardiovascular, Renal & Metabolism revenue down 12% and Infectious Disease revenue down 26%. Respiratory & Immunology was stronger, growing 9%.
There are also clinical-development risks, with AstraZeneca reporting that its CARDIO-TTRansform trial did not meet its primary efficacy endpoint, even while maintaining that it remains on track toward its $80 billion 2030 revenue ambition.
Those setbacks are significant for investors to notice because a pharmaceutical company’s valuation ultimately depends on successfully replacing products and expanding its pipeline. A large pipeline is valuable only if enough candidates eventually become commercial medicines. We meticulously crafted a list of the 7 Best Pharma Stocks to Invest In Now. Access the complete list here.
Does the Valuation Make Sense?
At roughly 14.6 times forward earnings, AstraZeneca PLC (NYSE:AZN) does not appear to be priced for perfection. The stock has declined over the past year even as core EPS increased 11% in the first half and management maintained its low-double-digit earnings-growth outlook.
The valuation therefore looks reasonably supported by the company’s current fundamentals, particularly its oncology franchise and broad late-stage pipeline. But the stock’s discount to the broader market will only become an opportunity if AstraZeneca can continue converting those pipeline investments into commercial growth.
For now, AstraZeneca looks more compelling as a growth company trading at a relatively moderate earnings multiple than as a traditional value stock. The key risk is not the current valuation itself, but whether the pipeline can deliver enough new growth to sustain it.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center